AR072148A1 - Derivados de quinoxalindiona - Google Patents
Derivados de quinoxalindionaInfo
- Publication number
- AR072148A1 AR072148A1 ARP090102166A ARP090102166A AR072148A1 AR 072148 A1 AR072148 A1 AR 072148A1 AR P090102166 A ARP090102166 A AR P090102166A AR P090102166 A ARP090102166 A AR P090102166A AR 072148 A1 AR072148 A1 AR 072148A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- coa
- hal
- mono
- nha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a compuestos de la formula (1) en la que X, Y, Z denotan cada uno, de modo independiente entre s¡, N o CR4, excluyendo los compuestos en los que X=Z=N, R1 denota H, A, COA, COOR5, CONR6R7, Ar o Het, R2, R3 denotan cada uno, de modo independiente entre s¡, H o A', R4 denota H, A, OH, OA, Hal, NH2, NHA, NA2, NO2, COA, COOR5, CONR6R7, CN, Ar o Het, R5 denota H o A', R6, R7 denotan cada uno, de modo independiente entre s¡, H, A, Ar o Het1, R6 y R7 tambien denotan juntos (CH2)m; Ar denota fenilo, naftilo o bifenilo, cada uno de los cuales no est sustituido o est mono-, di-, ri-, tetra- o pentasustituido con A, Hal, OA, OH, CHO, COA, NH2, NHA, NA2, NO2, COOA, COOH, CONH2, CONA, CONA2, SO2A, CN, C(=NH)NH2 y/o C(=NH)NHOH, Het denota un heterociclo mono- o bic¡clico saturado, insaturado o arom tico que tiene de 1 a 4 tomos de N, O y/o S, que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, CHO, COA, COOH, COOA, CN, NO2, NH2, NHA, NA2, CONH2, CONHA, CONA2 y/u =O, Het1 denota un heterociclo mono- o bic¡clico insaturado o arom tico que tiene de 1 a 4 tomos de N, O y/o S, que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, CHO, COA, COOH, COOA, CN, NO2, NH2, NHA, NA2, CONH2, CONHA y/o CONA2, A denota alquilo no ramificado o ramificado C1-10, en donde uno o dos grupos no adyacentes CH y/o CH2 pueden estar reemplazados por O y/o NH y/o adem s, 1-7 tomos de H pueden estar reemplazados por OH, F y/o Cl, o denota cicloalquilo C3-7, A' denota alquilo no ramificado o ramificado C1-6, en donde 1-7 tomos de H pueden estar reemplazados por F y/o Cl, Hal denota F, Cl, Br o I, m 2, 3, 4, 5 o 6, y sus sales y estereoisomeros farmaceuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Incluyendo sus composiciones farmaceuticas y su uso en el tratamiento y/o la prevencion de diabetes, s¡ndrome metabolico, obesidad, c ncer, inflamacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290564 | 2008-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072148A1 true AR072148A1 (es) | 2010-08-11 |
Family
ID=40823394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102166A AR072148A1 (es) | 2008-06-16 | 2009-06-16 | Derivados de quinoxalindiona |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8329698B2 (es) |
| EP (1) | EP2285786B1 (es) |
| JP (1) | JP5596676B2 (es) |
| KR (1) | KR101641391B1 (es) |
| CN (1) | CN102066342B (es) |
| AR (1) | AR072148A1 (es) |
| AU (1) | AU2009259754B2 (es) |
| BR (1) | BRPI0915064B8 (es) |
| CA (1) | CA2728018C (es) |
| CO (1) | CO6321252A2 (es) |
| CY (1) | CY1114737T1 (es) |
| DK (1) | DK2285786T3 (es) |
| EA (1) | EA020236B1 (es) |
| EC (1) | ECSP11010760A (es) |
| ES (1) | ES2436195T3 (es) |
| HK (1) | HK1157784A1 (es) |
| HR (1) | HRP20131069T1 (es) |
| IL (1) | IL209421A (es) |
| MX (1) | MX2010013577A (es) |
| MY (1) | MY155695A (es) |
| NZ (1) | NZ590503A (es) |
| PL (1) | PL2285786T3 (es) |
| PT (1) | PT2285786E (es) |
| SI (1) | SI2285786T1 (es) |
| WO (1) | WO2009152909A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| NZ731797A (en) | 2012-04-24 | 2018-08-31 | Vertex Pharma | Dna-pk inhibitors |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| EP3941496A4 (en) * | 2019-03-18 | 2022-11-23 | University of Washington | METHOD OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS |
| CN110642798B (zh) * | 2019-11-10 | 2020-07-24 | 湖南科技学院 | 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| CN116322663A (zh) | 2020-09-30 | 2023-06-23 | 比奥维拉迪维治疗股份有限公司 | Ampk激活剂及其使用方法 |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| CN116615199A (zh) * | 2020-11-26 | 2023-08-18 | 株式会社Lg化学 | 作为二酰基甘油激酶抑制剂的杂环化合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| CN1248249A (zh) | 1997-02-18 | 2000-03-22 | 美国家用产品公司 | 多巴胺激动剂5－氨基烷氧基－1,4－二氢喹喔啉－2,3－二酮类化合物 |
| AU2002314101A1 (en) * | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh &Co. Kg | Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| JP2007517800A (ja) * | 2004-01-06 | 2007-07-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての（３−オキソ−３，４−ジヒドロ−キノキサリン−２−イル−アミノ）−ベンズアミド誘導体および関連化合物 |
| MY139645A (en) | 2004-02-11 | 2009-10-30 | Amgen Inc | Vanilloid receptor ligands and their use in treatments |
| WO2007136465A2 (en) * | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
| FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2009
- 2009-05-19 EP EP09765489.1A patent/EP2285786B1/en active Active
- 2009-05-19 ES ES09765489T patent/ES2436195T3/es active Active
- 2009-05-19 EA EA201100007A patent/EA020236B1/ru not_active IP Right Cessation
- 2009-05-19 WO PCT/EP2009/003538 patent/WO2009152909A1/en active Application Filing
- 2009-05-19 AU AU2009259754A patent/AU2009259754B2/en active Active
- 2009-05-19 MY MYPI2010005917A patent/MY155695A/en unknown
- 2009-05-19 KR KR1020117000992A patent/KR101641391B1/ko active IP Right Grant
- 2009-05-19 JP JP2011513895A patent/JP5596676B2/ja active Active
- 2009-05-19 SI SI200930812T patent/SI2285786T1/sl unknown
- 2009-05-19 PL PL09765489T patent/PL2285786T3/pl unknown
- 2009-05-19 CN CN2009801227397A patent/CN102066342B/zh active Active
- 2009-05-19 NZ NZ590503A patent/NZ590503A/xx unknown
- 2009-05-19 MX MX2010013577A patent/MX2010013577A/es active IP Right Grant
- 2009-05-19 PT PT97654891T patent/PT2285786E/pt unknown
- 2009-05-19 DK DK09765489.1T patent/DK2285786T3/da active
- 2009-05-19 CA CA2728018A patent/CA2728018C/en active Active
- 2009-05-19 US US12/997,641 patent/US8329698B2/en active Active
- 2009-05-19 BR BRPI0915064A patent/BRPI0915064B8/pt active IP Right Grant
- 2009-06-16 AR ARP090102166A patent/AR072148A1/es active IP Right Grant
-
2010
- 2010-11-18 IL IL209421A patent/IL209421A/en active IP Right Grant
- 2010-12-14 CO CO10156748A patent/CO6321252A2/es active IP Right Grant
-
2011
- 2011-01-14 EC EC2011010760A patent/ECSP11010760A/es unknown
- 2011-11-16 HK HK11112373.9A patent/HK1157784A1/xx unknown
-
2012
- 2012-08-24 US US13/593,722 patent/US8674097B2/en active Active
-
2013
- 2013-11-08 HR HRP20131069AT patent/HRP20131069T1/hr unknown
- 2013-12-27 CY CY20131101166T patent/CY1114737T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072148A1 (es) | Derivados de quinoxalindiona | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR071530A1 (es) | Derivados de tienopiridonas como activadores de proteina quinasa activa-dos por amp (ampk) | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR082414A1 (es) | Carboxamidas azaheterociclicas biciclicas utiles para tratar enfermedades hiperproliferativas e inflamatorias, composiciones farmaceuticas que las contienen y procedimiento para prepararlas | |
| AR056347A1 (es) | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas | |
| AR075396A1 (es) | Derivados de quinazolinas y composiciones farmaceuticas | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR080328A1 (es) | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros | |
| ECSP099706A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor | |
| AR082101A1 (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR090602A1 (es) | AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2 | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ECSP077648A (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| AR067082A1 (es) | Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales. | |
| AR093725A1 (es) | Quinazolincarboxamida azetidinas | |
| AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
| AR083402A1 (es) | Pirrolidinonas como inhibidores de metap-2 | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |